TPX-4589
- Generic Name
- TPX-4589
- Drug Type
- Biotech
- Background
TPX-4589 is an antibody-drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE.
LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.
Phase 3
Recruiting
- Conditions
- Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
- Interventions
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- LaNova Medicines Zhejiang Co., Ltd.
- Target Recruit Count
- 375
- Registration Number
- NCT06351020
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Shanghai East Hospital, Shanghai, Shanghai, China
Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody
Phase 1
Recruiting
- Conditions
- Biliary Tract CancerCandonilimabClaudin 18.2
- Interventions
- Drug: cardonilizumab
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 96
- Registration Number
- NCT05994001
- Locations
- 🇨🇳
Zhongshan hospital, Fudan University, Shanghai, China
Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- LaNova Australia Pty Limited
- Target Recruit Count
- 20
- Registration Number
- NCT05188664
- Locations
- 🇦🇺
The Alfred, Melbourne, Australia
Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT05001516
- Locations
- 🇺🇸
Local Institution - 0017, Fullerton, California, United States
🇺🇸Local Institution - 0012, Lafayette, Indiana, United States
🇺🇸Local Institution - 0013, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath